---
layout: default
title: Peginterferon Beta-1A
parent: 僅模型預測 (L5)
nav_order: 338
evidence_level: L5
indication_count: 10
---

# Peginterferon Beta-1A
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Peginterferon beta-1a: From Undocumented Indication to Heart Neoplasm

## One-Sentence Summary

Peginterferon beta-1a (DrugBank ID: DB09122) has no documented original indication or mechanism-of-action data in this evidence pack. The TxGNN model predicts a possible association with **Heart Neoplasm**, but this prediction is based purely on knowledge-graph embedding similarity — **no clinical trials and no literature** currently support it, and the model's own rationale text notes no known pathophysiological link between interferon beta and cardiac tumours.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in available data |
| Predicted New Indication | Heart Neoplasm |
| TxGNN Prediction Score | 94.10% |
| Evidence Level | L5 (model prediction only) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Peginterferon beta-1a is not available in this evidence pack, and no original indication is on record to compare against. Based on general pharmacological class knowledge, interferon beta agents are known for antiproliferative and immunomodulatory effects, which is the presumed basis for the TxGNN embedding association — but this evidence pack contains no data confirming that link for this specific drug.

Importantly, the model's own repurposing rationale for this candidate is explicitly skeptical: it states there is no known pathophysiological connection between interferon beta and heart neoplasms (which are predominantly benign structural lesions such as rhabdomyomas or myxomas, not immune- or proliferation-driven tumours in the way interferon beta's mechanism would target). The rationale characterizes this as a knowledge-graph similarity artifact rather than a mechanistically grounded hypothesis.

For context, TxGNN also flagged four additional candidate indications for this drug at comparable confidence (congenital ventricular septal defect, heart conduction disease, borderline ovarian serous tumor, rete ovarii cystadenoma) — all with the same L5 evidence level, no supporting trials or literature, and rationale text that similarly notes weak or absent mechanistic plausibility. This pattern suggests the current signal set for this drug is not yet strong enough to prioritize any single indication.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Denmark Market Information

No marketing authorisations are currently registered for this drug in Denmark (market status: not marketed; total authorisations: 0).

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No drug interaction data, key warnings, or contraindications are currently available in this evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No clinical trials, no literature, no mechanism-of-action data, and no marketing history in Denmark support this candidate. The prediction rests solely on a TxGNN similarity score, and the model's own rationale acknowledges no credible mechanistic link to heart neoplasm — evidence level L5 with decision stage S0 confirms this is not yet actionable.

**To proceed, the following is needed:**
- Product label / SmPC data (warnings, contraindications) — currently a blocking data gap (DG001)
- Mechanism of action (MOA) data from DrugBank or primary literature (DG002)
- Confirmation of the drug's original approved indication(s)
- Preclinical or case-level evidence specifically linking interferon beta to cardiac neoplasm before further evaluation is warranted
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

